Literature DB >> 2032522

Inhibitors of hepatic DNA synthesis in fulminant hepatic failure.

R D Hughes1, H Yamada, C D Gove, R Williams.   

Abstract

In certain etiological groups of patients with fulminant hepatic failure, poor survival may be due to lack of liver regeneration. In vitro experiments have shown that fulminant hepatic failure serum is cytotoxic to rabbit hepatocytes and inhibits DNA synthesis on short-term incubation with isolated regenerating rat hepatocytes. When fulminant hepatic failure serum is injected into partially hepatectomized rats at the time of maximal DNA synthesis, [3H]thymidine incorporation into hepatic DNA is reduced significantly. The effect is greater with sera obtained from patients with fulminant hepatic failure due to non-A, non-B hepatitis or an adverse drug reaction and is associated with a less than 10,000-dalton fraction. No stimulation of DNA synthesis is observed with injection of the greater than 10,000-dalton serum fraction into normal rats. In preliminary experiments, no increase in epidermal growth factor production has been found in liver failure. Overall, the substances present in fulminant hepatic failure serum appear to be inhibitory rather than stimulatory for liver cell regeneration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032522     DOI: 10.1007/bf01311242

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  11 in total

1.  Use of 3 H-thymidine for measurement of DNA synthesis in rat liver--a warning.

Authors:  C G Morley; H S Kingdon
Journal:  Anal Biochem       Date:  1972-01       Impact factor: 3.365

2.  Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage.

Authors:  B G Gazzard; B Portmann; I M Murray-Lyon; R Williams
Journal:  Q J Med       Date:  1975-10

3.  Human serum does contain a high molecular weight hepatocyte growth factor: studies pre- and post-hepatic resection.

Authors:  C Selden; R Johnstone; H Darby; S Gupta; H J Hodgson
Journal:  Biochem Biophys Res Commun       Date:  1986-08-29       Impact factor: 3.575

4.  Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure.

Authors:  E Gohda; H Tsubouchi; H Nakayama; S Hirono; K Takahashi; M Koura; S Hashimoto; Y Daikuhara
Journal:  Exp Cell Res       Date:  1986-09       Impact factor: 3.905

5.  Hepatotoxic effects of sera from patients with fulminant hepatitis B on isolated rat hepatocytes in culture.

Authors:  T Haas; C J Holloway; V Osterthun; I Trautschold
Journal:  J Clin Chem Clin Biochem       Date:  1981-05

6.  The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes.

Authors:  R D Hughes; A M Cochrane; A D Thomson; I M Murray-Lyon; R Williams
Journal:  Br J Exp Pathol       Date:  1976-06

7.  Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure.

Authors:  E Gohda; H Tsubouchi; H Nakayama; S Hirono; O Sakiyama; K Takahashi; H Miyazaki; S Hashimoto; Y Daikuhara
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

8.  Rapid inhibition of DNA synthesis in hepatocytes from regenerating rat liver by serum from patients with fulminant hepatic failure.

Authors:  C D Gove; R D Hughes; R Williams
Journal:  Br J Exp Pathol       Date:  1982-10

9.  Hepatopoietin A: partial characterization and trypsin activation of a hepatocyte growth factor.

Authors:  F J Thaler; G K Michalopoulos
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

10.  Fulminant hepatitis: Mayo Clinic experience with 34 cases.

Authors:  J Rakela; S M Lange; J Ludwig; W P Baldus
Journal:  Mayo Clin Proc       Date:  1985-05       Impact factor: 7.616

View more
  2 in total

1.  Future of bioartificial liver support.

Authors:  Robert Afm Chamuleau
Journal:  World J Gastrointest Surg       Date:  2009-11-30

2.  Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model.

Authors:  D W Y Ho; S T Fan; J To; Y H Woo; Z Zhang; C Lau; J Wong
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.